

Expert Second Opinion: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements best describes results from the Phase III inMIND study evaluating the addition of tafasitamab to lenalidomide/rituximab ( $R^2$ ) for patients with relapsed/refractory (R/R) follicular lymphoma?
  - a. Tafasitamab significantly improved progression-free survival (PFS)
  - b. Tafasitamab significantly improved PFS, with overall survival (OS) trending in favor of tafasitamab**
  - c. No significant improvement in PFS or OS was reported with tafasitamab
2. In the Phase III SUNMO study, which of the following regimens demonstrated a significant improvement in median PFS in comparison to rituximab with gemcitabine/oxaliplatin (GemOx) for patients with R/R diffuse large B-cell lymphoma (DLBCL) who were not eligible for transplant?
  - a. Glofitamab with polatuzumab vedotin
  - b. Epcoritamab with GemOx
  - c. Mosunetuzumab with polatuzumab vedotin**
  - d. Odronextamab with GemOx
  - e. None of the above
3. The Phase III ECHELON-3 study evaluating brentuximab vedotin (BV) with  $R^2$  versus  $R^2$  alone for R/R DLBCL reported which association between CD30 expression level and BV/ $R^2$  clinical activity?
  - a. A markedly higher complete response (CR) rate with BV/ $R^2$  among patients with high CD30 expression levels
  - b. Improvement in objective response rate with BV/ $R^2$ , regardless of CD30 expression level**
  - c. CD30 expression levels were not analyzed in the ECHELON-3 study
4. In the LOTIS-7 study evaluating the combination of glofitamab and loncastuximab tesirine for R/R non-Hodgkin lymphoma, what was the approximate overall response rate across all dose levels?
  - a. 29%
  - b. 40%
  - c. 62%
  - d. 93%**
5. Which of the following outcomes best describes 5-year efficacy findings with tafasitamab and lenalidomide for patients with R/R DLBCL in the Phase II L-MIND trial?
  - a. Objective response rate (ORR) 17% with no CRs
  - b. ORR 37% with 10% CRs
  - c. ORR 57% with >40% CRs**